Biotech Startups

Terray is a drug discovery company that combines proprietary hardware, large-scale experimental datasets, and AI through its EMMI platform to design small molecule medicines. It develops therapeutic candidates by integrating high-throughput experimentation with machine learning.

9 investors

Turbine develops computational simulations of cells to accelerate drug discovery and development in oncology, using in silico predictions validated through wet lab experiments.

9 investors

Umami Bioworks develops cultivated seafood using cell biology and bioprocess engineering technologies. The company produces sustainable, affordable seafood products intended for consumer markets concerned with health, ocean conservation, and environmental impact.

9 investors

Upstream Bio is a biotechnology company that sponsors clinical trials to develop products under investigation. It works with clinical study staff, principal investigators, and healthcare practitioners at study sites conducting its trials.

9 investors

Valink Therapeutics develops bispecific antibody-drug conjugates (ADCs) for therapeutic applications, combining high-throughput discovery, antibody engineering, and medicinal chemistry capabilities.

9 investors

Verona Pharma develops treatments for chronic lung conditions. As of October 2025, it and its subsidiaries are part of Merck & Co., Inc.

9 investors

Cultivated animal products company.

9 investors

Wildtype grows salmon directly from fish cells using cellular agriculture, allowing production of seafood without wild-caught or farmed fish. The company serves restaurants and consumers seeking sustainable seafood with reduced contaminants.

9 investors

X-Therma develops a proprietary peptoid-based technology that inhibits ice crystal formation to enable long-term sub-zero preservation and transport of cells, tissues, organs, and other biologics. Its products, including the XT-ViVo preservation solution and TimeSeal organ transport device, target organ and biologic preservation for transplantation.

9 investors

Xaira develops AI and machine learning tools for drug discovery and protein design, serving pharmaceutical and biotech companies.

9 investors

Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment. Its approach aims to achieve durable efficacy for cancer patients while avoiding the severe systemic side effects of conventional immuno-oncology agents.

9 investors

Yoneda Labs applies AI/ML and high-throughput experimentation (HTE) to chemical reaction optimization, including cross-coupling reactions, for the life sciences and pharmaceutical research market. The company combines chemistry research, software, and robotics to optimize synthetic reactions.

9 investors

Zafrens develops a unified drug discovery platform that integrates isolation, imaging, and sequencing workflows to accelerate the identification of therapeutic compounds across modalities. The platform leverages AI and high-resolution data to compress timelines in drug development.

9 investors

Zenas BioPharma is a biopharmaceutical company developing therapies for autoimmune diseases, with two late-stage drug candidates: obexelimab, a bifunctional monoclonal antibody targeting CD19 and FcγRIIb to suppress B cell activity, and orelabrutinib, an oral BTK inhibitor. Its products are aimed at patients with multiple autoimmune conditions with unmet medical needs.

9 investors

Occam Razor develops drug discovery technology using digital science to target neurodegenerative diseases, focusing initially on Parkinson's disease and brain aging.

8 investors

10x Genomics offers single cell analysis technology, including its Flex assay and Flex Apex product, which use probe-based chemistry and plate-based multiplexing to profile fresh, frozen, and FFPE samples for researchers. The tools support applications in cancer, immunology, and neuroscience, enabling gene expression and multiomic profiling of cell surface protein, intracellular protein, and CRISPR guides.

8 investors

An AI-native biotech company that combines multimodal data, AI models, and high-throughput lab automation to discover small and large molecule therapeutics. Its infrastructure supports AI-enabled drug discovery across multiple therapeutic modalities.

8 investors

Adcendo develops antibody-drug conjugates (ADCs) targeting cancers with high unmet medical need. The company engineers therapeutic medicines designed to deliver clinically differentiated outcomes for cancer patients.

8 investors

Avalo uses machine learning to accelerate crop breeding, developing improved plant varieties such as fast-maturing broccoli, adaptive sugarcane, heat-resilient tomatoes, and low-input cotton. It partners with farmers and agricultural producers to create crops with better yields, resource efficiency, and climate resilience.

8 investors

Aktis Oncology discovers and develops targeted radiopharmaceuticals for treating solid tumors. The company serves oncology patients and healthcare providers in the cancer care sector.

8 investors

Altis Biosystems builds RepliGut®, human intestinal tissue models grown from human intestinal stem cells that provide human-relevant preclinical data for drug absorption, metabolism, toxicity, and disease modeling. It serves pharmaceutical and life-science researchers as an alternative to animal studies and Caco-2 cell lines, offering ready-to-use kits and custom studies.

8 investors

Andes is a mission-driven company focused on protecting the planet and applying technology in a nature-related context. The about page emphasizes the team and hiring but gives limited concrete detail on the specific product or service.

8 investors

Ångström AI develops AI-powered physics simulations for pharmaceutical drug discovery, computing molecular properties like solubility, lipophilicity, and crystal structure stability to replace traditional lab experiments. The platform uses machine learning interatomic potentials and free energy calculations to accelerate and derisk solid form development for pharma companies.

8 investors

NASDAQ-listed company developing therapies for complement cascade-driven diseases in haematology, ophthalmology, and nephrology.

8 investors